Hemostasis and Vascular Inflammation

Inflammatory Diseases of Blood Vessels: Second Edition

Volumn , Issue , 2012, Pages 105-114

  Leung, Lawrence ^a,b   Morser, John ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregation; Coagulation; Dendritic cell; Immunity; Inflammation; Platelet; Protease activated receptor (PAR); Thrombin; Thrombomodulin

Indexed keywords

EID: 84875240789     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118355244.ch10     Document Type: Chapter

References (30)

1. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J ThrombHaemost 2007; 5(Suppl 1):24-31. 114 PART I Biology of Blood Vessels
2. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3:1800-14.
3. Vandendries ER, Hamilton JR, Coughlin SR, et al. PAR4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A 2007; 104:288-92.
4. Esmon CT. The protein C pathway. Chest 2003; 124:26S-32S.
5. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:345-57.
6. SaitoH,Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5:31-41.
7. Kearon C, Comp P, Douketis J, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 3:962-8.
8. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 2005; 280:19808-14.
9. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost 2008; 6:954-61.
10. Schuepbach RA, Feistritzer C, Fernandez JA, et al. Protection of vascular barrier integrity by activated protein C inmurine models depends on protease-activated receptor-1. Thromb Haemost 2009; 101:724-33.
11. Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008; 452:654-8.
12. Laterre PF. Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care 2007; 11(Suppl 5):S5.
13. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204:2439-48.
14. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451:1076-81.
15. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsingmultiple sclerosis. N Engl J Med 2010; 362:387-401.
16. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-15.
17. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103:1192-201.
18. Takagi T, Taguchi O, Aoki S, et al. Direct effects of protein S in ameliorating acute lung injury. J Thromb Haemost 2009; 7:2053-63.
19. Nishimura T, Myles T, Piliponsky AM, et al. Thrombinactivatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007; 109:1992-7.
20. Song JJ, Hwang I, Cho KH, et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121:3517-27.
21. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278:51059-67.
22. Sharif SA, Du X, Myles T, et al. Thrombin-activatable carboxypeptidase B-cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum 2009; 60:2902-12.
23. Du XY, Zabel BA, Myles T, et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem 2009; 284:751-8.
24. Shi CS, Shi GY, Hsiao SM, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008; 112:3661-70.
25. Hagiwara S, Iwasaka H, Matsumoto S, et al. In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 2010; 33:282-8.
26. Takagi T, Taguchi O, Toda M, et al. Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 2011; 183:31-42.
27. 141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid dc subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60.
28. 141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81.
29. Elzey BD, Schmidt NW, Crist SA, et al. Platelet-derived CD154 enables T-cell priming and protection against listeria monocytogenes challenge. Blood 2008; 111:3684-91.
30. Mueller A, Meiser A, McDonagh EM, et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol 2008; 83:875-82.